1. Home
  2. BZAI vs RIGL Comparison

BZAI vs RIGL Comparison

Compare BZAI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BZAI
  • RIGL
  • Stock Information
  • Founded
  • BZAI 2010
  • RIGL 1996
  • Country
  • BZAI United States
  • RIGL United States
  • Employees
  • BZAI N/A
  • RIGL N/A
  • Industry
  • BZAI
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BZAI
  • RIGL Health Care
  • Exchange
  • BZAI Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • BZAI 343.8M
  • RIGL 335.5M
  • IPO Year
  • BZAI N/A
  • RIGL 2000
  • Fundamental
  • Price
  • BZAI $4.66
  • RIGL $29.94
  • Analyst Decision
  • BZAI Strong Buy
  • RIGL Buy
  • Analyst Count
  • BZAI 3
  • RIGL 5
  • Target Price
  • BZAI $8.33
  • RIGL $38.20
  • AVG Volume (30 Days)
  • BZAI 4.3M
  • RIGL 493.3K
  • Earning Date
  • BZAI 11-13-2025
  • RIGL 11-04-2025
  • Dividend Yield
  • BZAI N/A
  • RIGL N/A
  • EPS Growth
  • BZAI N/A
  • RIGL N/A
  • EPS
  • BZAI N/A
  • RIGL 5.43
  • Revenue
  • BZAI $3,771,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • BZAI $2,295.50
  • RIGL $59.93
  • Revenue Next Year
  • BZAI $269.04
  • RIGL N/A
  • P/E Ratio
  • BZAI N/A
  • RIGL $5.41
  • Revenue Growth
  • BZAI 114.63
  • RIGL 105.62
  • 52 Week Low
  • BZAI $1.70
  • RIGL $13.57
  • 52 Week High
  • BZAI $29.61
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • BZAI 52.08
  • RIGL 49.33
  • Support Level
  • BZAI $4.11
  • RIGL $29.30
  • Resistance Level
  • BZAI $6.76
  • RIGL $31.92
  • Average True Range (ATR)
  • BZAI 0.65
  • RIGL 1.53
  • MACD
  • BZAI -0.10
  • RIGL 0.46
  • Stochastic Oscillator
  • BZAI 20.19
  • RIGL 65.52

About BZAI Blaize Holdings Inc. Common Stock

Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: